Stocks and Investing
Stocks and Investing
Tue, February 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mayank Mamtani Maintained (TGTX) at Strong Buy with Increased Target to $95 on, Feb 9th, 2021
Mayank Mamtani of B. Riley Securities, Maintained "TG Therapeutics, Inc." (TGTX) at Strong Buy with Increased Target from $90 to $95 on, Feb 9th, 2021.
Mayank has made no other calls on TGTX in the last 4 months.
There are 2 other peers that have a rating on TGTX. Out of the 2 peers that are also analyzing TGTX, 0 agree with Mayank's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mayank
- Edward White of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $79 on, Monday, February 8th, 2021
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $48 on, Wednesday, October 28th, 2020
Contributing Sources